These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36276066)

  • 1. Platelet-promoting drug delivery efficiency for inhibition of tumor growth, metastasis, and recurrence.
    Li X; Hu L; Tan C; Wang X; Ran Q; Chen L; Li Z
    Front Oncol; 2022; 12():983874. PubMed ID: 36276066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smart transformable nanomedicines for cancer therapy.
    Wang Y; Li S; Wang X; Chen Q; He Z; Luo C; Sun J
    Biomaterials; 2021 Apr; 271():120737. PubMed ID: 33690103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-associated-platelet-inspired nanomedicines for cancer therapy.
    Geranpayehvaghei M; Dabirmanesh B; Khaledi M; Atabakhshi-Kashi M; Gao C; Taleb M; Zhang Y; Khajeh K; Nie G
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1702. PubMed ID: 33538125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
    Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
    Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor vasculature-targeting nanomedicines.
    Zhang Y; He J
    Acta Biomater; 2021 Oct; 134():1-12. PubMed ID: 34271167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer nanomedicines harnessing tumor microenvironmental components.
    Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
    Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
    Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
    Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
    Jiang Z; Chu Y; Zhan C
    Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
    Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
    Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination antitumor therapy with targeted dual-nanomedicines.
    Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
    Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
    Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
    Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies of engineering nanomedicines for tumor retention.
    Qian X; Xu X; Wu Y; Wang J; Li J; Chen S; Wen J; Li Y; Zhang Z
    J Control Release; 2022 Jun; 346():193-211. PubMed ID: 35447297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Incorporated Nanomedicines for Cancer Therapy.
    Wu SY; Wu FG; Chen X
    Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-Assembled Nanomedicines for Anticancer and Antibacterial Applications.
    Zhou L; Qiu T; Lv F; Liu L; Ying J; Wang S
    Adv Healthc Mater; 2018 Oct; 7(20):e1800670. PubMed ID: 30080319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active targeting strategy in nanomedicines using anti-EGFR ligands - A promising approach for cancer therapy and diagnosis.
    Nguyen PV; Hervé-Aubert K; Chourpa I; Allard-Vannier E
    Int J Pharm; 2021 Nov; 609():121134. PubMed ID: 34571073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.